Can-Fite Reveals Applied Patent for Cannabinoid Formulations

Can-Fite BioPharma (NYSEAMERICAN:CANF) announced new findings in its collaboration with Univo Pharmaceuticals (TASE:UNVO) characterizing the effects of cannabinoids on diseases mediated through the A3 adenosine receptor (A3AR).

As quoted in the press release:

Joint research shows that certain cannabinoid-based formulations exert a highly potent beneficial effect on diseased cells by binding to A3AR, and these findings present new opportunities for the development of cannabinoids in the treatment of a variety of diseases in which there is an overexpression of A3AR. Can-Fite filed a patent application titled “Cannabinoids for use in treating A3 adenosine receptor-associated conditions” based on these findings, and covering all the clinical indications in which A3AR is overexpressed.

Can-Fite, a global leader in discovering and developing drugs which target A3AR, is collaborating with Univo Pharmaceuticals and utilizes its platform technology within the framework of this collaboration to develop cannabinoids for the treatment of large unmet medical needs. Can-Fite announced a strategic partnership with Univo Pharmaceuticals, a medical cannabis company, in September 2019, and Univo’s CEO Golan Bitton joined Can-Fite’s Board of Directors in December 2019.

Click here to read the full press release.